New drug combo targets tough lung cancer in early trial

NCT ID NCT03810807

Completed Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated Apr 29, 2026 · Updated 18 times

Summary

This early-phase study tested the safety of combining two targeted drugs, dacomitinib and osimertinib, for people with a specific type of advanced lung cancer (EGFR mutant) that had not been treated with similar drugs before. The goal was to find the safest dose and see how well the combination worked. The study involved 22 participants and focused on controlling the disease, not curing it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.

METASTATIC NON-SMALL CELL LUNG CANCER